Delving into the Latest Updates on MK-0916 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

11β-HSD

Action

inhibitors

Mechanism

11β-HSD inhibitors(11-beta-hydroxysteroid dehydrogenase inhibitors)

Therapeutic Areas

Cardiovascular DiseasesEndocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Diabetes Mellitus, Type 2HypertensionMetabolic Syndrome

Originator Organization

Merck & Co., Inc.

Active Organization-

Inactive Organization

Merck Sharp & Dohme Corp.Merck Sharp & Dohme LLC

License Organization-

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

The objective of this study is to evaluate the safety and efficacy of two investigational drugs (MK-0736 and MK-0916) in lowering blood pressure and body weight in patients with hypertension (high blood pressure).
This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).

Start Date01 Nov 2005

Sponsor / Collaborator

Merck Sharp & Dohme LLC

NCT00543595

/ CompletedPhase 2

MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)

This study will test the safety and effectiveness of MK0916 in patients with Type 2 Diabetes Mellitus and Metabolic Syndrome.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Start Date01 Aug 2004

Sponsor / Collaborator

Merck Sharp & Dohme Corp.

100 Clinical Results associated with MK-0916

Login to view more data

100 Translational Medicine associated with MK-0916

Login to view more data

100 Patents (Medical) associated with MK-0916

Login to view more data

2

Literatures (Medical) associated with MK-0916

01 Jun 2011·Diabetes, obesity & metabolismQ2 · MEDICINE

Effects of an 11 β ‐hydroxysteroid dehydrogenase type 1 inhibitor, MK‐0916, in patients with type 2 diabetes mellitus and metabolic syndrome

Q2 · MEDICINE

Article

Author: Plotkin, D. ; Thach, C. ; Donahue, S. ; Lai, E. ; Springer, M. S. ; Kaufman, K. D. ; Hermanowski-Vosatka, A. ; Feig, P. U. ; Klein, E. J. ; Shah, S.

01 May 2011·Journal of the American Society of Hypertension : JASH

Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension

Article

Author: Ruck, Rae Ann ; Feig, Peter U. ; Ryan, Nicholas W. ; Hwang, Peggy M. T. ; Shah, Sukrut ; Gibson, Kendra ; Jia, Gang ; Zhang, John ; Hermanowski-Vosatka, Anne ; Langdon, Ronald B.

100 Deals associated with MK-0916

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypertension	Phase 2	-	Merck Sharp & Dohme LLC	01 Nov 2005
Diabetes Mellitus, Type 2	Phase 2	-	Merck Sharp & Dohme Corp.	01 Aug 2004
Metabolic Syndrome	Phase 2	-	Merck Sharp & Dohme Corp.	01 Aug 2004

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00274716 (0736-003, CTgov)	Phase 2	Hypertension	249	Placebo+MK0736 (High BMI:MK-0736 2mg→Placebo)	qexzxcrqrl = fipqbvuort cjkdkpeysu (xrqrrdufoc, jcqvhipylo - pgcmmgnary) View more	-	14 Feb 2014
				Placebo+MK0736 (High BMI:MK-0736 7mg→Placebo)	qexzxcrqrl = pakqrkaszc cjkdkpeysu (xrqrrdufoc, ljpvwtcpea - jbrcizcmhj) View more